MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 12-16-2023
Covetrus EBITDA 2011-2025 | CVET
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Covetrus
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 148 M | 98 M | -843 M | 201 M | 194 M | 187 M | 162 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 201 M | -843 M | 21 M |
Quarterly EBITDA Covetrus
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 45 M | 46 M | - | 38 M | 34 M | 40 M | -19 M | 14 M | 37 M | 20 M | -25 M | -917 M | 36 M | 21 M | 33 M | 50 M | 54 M | 48 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 54 M | -917 M | -26.2 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Health information services industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
1.43 B | - | - | $ 27.9 B |  USA |
 |
Computer Programs and Systems
CPSI
|
-40.7 M | - | 4.4 % | $ 133 M | USA |
 |
Accolade
ACCD
|
-38.6 M | - | 0.29 % | $ 206 M | USA |
 |
Castlight Health, Inc.
CSLT
|
-5.95 M | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
140 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
187 M | - | - | $ 6.37 B | USA |
 |
Change Healthcare
CHNG
|
691 M | - | - | $ 9.03 B | USA |
 |
Evolent Health
EVH
|
70.8 M | $ 4.11 | -0.48 % | $ 385 M | USA |
 |
Health Catalyst
HCAT
|
-28.4 M | $ 2.34 | -4.82 % | $ 141 M | USA |
 |
HealthStream
HSTM
|
62.5 M | $ 24.4 | 0.95 % | $ 741 M | USA |
 |
iCAD
ICAD
|
-6.03 M | - | - | $ 102 M | USA |
 |
Akerna Corp.
KERN
|
-6.57 M | - | - | $ 161 M | USA |
 |
HealthEquity
HQY
|
271 M | $ 96.06 | -0.75 % | $ 8.22 B | USA |
 |
OptimizeRx Corporation
OPRX
|
-24 M | $ 13.18 | -1.35 % | $ 226 M | USA |
 |
American Well Corporation
AMWL
|
-185 M | $ 4.68 | 1.3 % | $ 70.2 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
253 M | - | -10.39 % | $ 886 M | USA |
 |
Progyny
PGNY
|
19 M | $ 26.39 | -1.2 % | $ 2.26 B | USA |
 |
Premier
PINC
|
119 M | $ 28.26 | - | $ 2.33 B | USA |
 |
MTBC
MTBC
|
23.3 M | - | -0.58 % | $ 51.7 M | USA |
 |
GoodRx Holdings
GDRX
|
135 M | $ 2.72 | -3.72 % | $ 1.05 B | USA |
 |
Schrödinger
SDGR
|
-203 M | $ 18.41 | 1.99 % | $ 1.34 B | USA |
 |
Omnicell
OMCL
|
82.6 M | $ 43.31 | -1.25 % | $ 1.99 B | USA |
 |
1Life Healthcare
ONEM
|
-197 M | - | - | $ 3.37 B | USA |
 |
Phreesia
PHR
|
-107 M | $ 16.68 | 2.71 % | $ 910 M | USA |
 |
So-Young International
SY
|
-579 M | $ 2.92 | -5.66 % | $ 232 M |  China |
 |
Signify Health
SGFY
|
63.3 M | - | -0.02 % | $ 7.21 B | USA |
 |
R1 RCM
RCM
|
223 M | - | - | $ 3.81 B | USA |
 |
10x Genomics
TXG
|
-230 M | $ 15.77 | 2.01 % | $ 1.85 B | USA |
 |
NantHealth
NH
|
-35.3 M | - | -46.64 % | $ 10.4 M | USA |
 |
NextGen Healthcare
NXGN
|
20.8 M | - | - | $ 1.6 B | USA |
 |
Veeva Systems
VEEV
|
435 M | $ 219.17 | -1.81 % | $ 35.2 B | USA |
 |
Zhongchao
ZCMD
|
-110 K | $ 0.58 | -3.18 % | $ 3.02 M | China |
 |
Streamline Health Solutions
STRM
|
-3.18 M | - | - | $ 21.4 M | USA |
 |
Teladoc Health
TDOC
|
-658 M | $ 7.36 | -2.65 % | $ 1.26 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
-45.6 M | - | - | $ 255 M | USA |
 |
SCWorx Corp.
WORX
|
-1.26 M | $ 0.21 | 5.86 % | $ 306 K | USA |